The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib in Ulcerative Colitis Pharmaceutical Investing
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab in Crohn's Disease Pharmaceutical Investing
NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022 Market News
Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy Pharmaceutical Investing
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV Pharmaceutical Investing
Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101 Pharmaceutical Investing
Awakn Life Sciences Files Patent Cooperation Treaty Application for the Treatment of Behavioral Addictions Company News
Bristol Myers Squibb to Participate in Bernstein's 38th Annual Strategic Decisions Conference Pharmaceutical Investing
Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase Medical Device Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
